Timber Pharmaceuticals (TMBR)

Company Profile

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma.

Company profile

Ticker

TMBR

Exchange

NYSEAMERICAN

Website

www.timberpharma.com

CEO

John Koconis

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

BioPharmX Corp, THOMPSON DESIGNS INC

SEC CIK

0001504167

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

BioPharmX, Inc. • Timber Pharmaceuticals Australia Pty Ltd. • Timber Pharmaceuticals LLC ...

IRS number

593843182

TMBR stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

3 Feb 23

8-K

Regulation FD Disclosure

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

14 Nov 22

Material Modifications to Rights of Security Holders

9 Nov 22

8-K

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

8 Nov 22

8-K

Timber Pharmaceuticals Announces Halt of Common Stock Trading

3 Nov 22

8-K

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital

Latest ownership filings

View all

Edward J Sitar

16 Dec 22

SC 13G

INTRACOASTAL CAPITAL, LLC

Financial summary

Financial statements Chart TMBR financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Jan 20	Jan 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.22 mm	11.22 mm	11.22 mm	11.22 mm	11.22 mm	11.22 mm
Cash burn (monthly)	(no burn)	(no burn)	1.04 mm	1.54 mm	1.38 mm	1.25 mm
Cash used (since last report)	n/a	n/a	5.96 mm	8.80 mm	7.87 mm	7.14 mm
Cash remaining	n/a	n/a	5.27 mm	2.43 mm	3.35 mm	4.08 mm
Runway (months of cash)	n/a	n/a	5.1	1.6	2.4	3.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

TMBR institutional ownership history Ownership history

10.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	17	16	+6.3%
Opened positions	6	3	+100.0%
Closed positions	5	2	+150.0%
Increased positions	4	7	-42.9%
Reduced positions	1	2	-50.0%

13F shares	Current	Prev Q	Change
Total value	4.48 mm	3.79 mm	+18.4%
Total shares	15.23 mm	5.20 mm	+192.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Intracoastal Capital	5.76 mm	$553.00 k	NEW
Vanguard	4.12 mm	$495.00 k	+251.7%
TardiMed Sciences	3.31 mm	$3.19 mm	0.0%
Geode Capital Management	787.08 k	$94.00 k	+228.9%
Two Sigma Securities	325.66 k	$39.00 k	+588.8%
Susquehanna International	320.45 k	$38.00 k	NEW
BK Bank Of New York Mellon	291.38 k	$35.00 k	NEW
NTRS Northern Trust	121.89 k	$15.00 k	0.0%
BCS Barclays	103.60 k	$12.00 k	0.0%
UBS UBS Group AG - Registered Shares	44.74 k	$5.00 k	-9.4%

Largest transactions	Shares	Bought/sold	Change
Intracoastal Capital	5.76 mm	+5.76 mm	NEW
Vanguard	4.12 mm	+2.95 mm	+251.7%
Geode Capital Management	787.08 k	+547.75 k	+228.9%
Susquehanna International	320.45 k	+320.45 k	NEW
BK Bank Of New York Mellon	291.38 k	+291.38 k	NEW
Two Sigma Securities	325.66 k	+278.38 k	+588.8%
STT State Street	0.00	-112.10 k	EXIT
C Citigroup	0.00	-20.00 k	EXIT
Renaissance Technologies	0.00	-15.81 k	EXIT
Victory Capital Management	14.58 k	+14.58 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TMBR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Dec 22	Sitar Edward J	Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	1.629	2,500	4.07 k	5,800
15 Apr 22	Lubor Gaal	Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0	100,000	0.00	100,000
15 Apr 22	Lubor Gaal	Stock Option Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0.307	100,000	30.70 k	100,000
15 Apr 22	Gianluca Pirozzi	Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0	100,000	0.00	100,000
15 Apr 22	Gianluca Pirozzi	Stock Option Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0.307	100,000	30.70 k	100,000
15 Apr 22	Sitar Edward J	Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0	150,000	0.00	165,000
15 Apr 22	Sitar Edward J	Stock Option Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0.307	150,000	46.05 k	150,000
15 Apr 22	Cohen David E	Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0	100,000	0.00	100,000
15 Apr 22	Cohen David E	Stock Option Common Stock, par value $0.001 per share	Grant	Acquire A	No	No	0.307	100,000	30.70 k	100,000